🇺🇸 FDA
Patent

US 10533174

Splice-region antisense composition and method

granted A61KA61K38/00A61P

Quick answer

US patent 10533174 (Splice-region antisense composition and method) held by Sarepta Therapeutics, Inc. expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/00, A61P, A61P13/08, A61P17/00